Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment

Protagonist Therapeutics PTGX reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ, on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235).

JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.

Also Read: Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study

Although peptides typically have low oral bioavailability, the high potency of JNJ-2113 and its oral stability indicated the potential for systemic activity beyond the gastrointestinal tract in rat models of inflammation and colitis.

In a rat trinitrobenzene sulfonic acid (TNBS)-induced colitis model, efficacy was observed as measured by attenuation of weight loss and colon inflammation with oral doses of JNJ-2113 as low as 0.3 mg/kg/day.

In an IL-23-induced rat skin inflammation model, orally dosed JNJ-2113 achieved inhibition of inflammation, equivalent to an IL-23 antibody, and reduced IL-17 and IL-22 cytokines.

Oral treatment with JNJ-2113 provided selective systemic IL-23 pathway inhibition in preclinical models.

"We look forward to the presentation of the Phase 2b FRONTIER 1 study data in adults with moderate-to-severe plaque psoriasis later this year," said Dinesh Patel, President & CEO.

Price Action: PTGX shares are up 1.97% at $25.21 on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!